CHM 1101 / Chimeric Therap 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
CHM 1101 / Chimeric Therap
NCT04214392: Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma

Recruiting
1
36
US
Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT delivery), Chlorotoxin-CD28-CD3z-CD19t-expressing CAR T-cells, Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT/ICV dual delivery)
City of Hope Medical Center, National Cancer Institute (NCI)
Recurrent Glioblastoma, Recurrent Malignant Glioma, Recurrent WHO Grade II Glioma, Recurrent WHO Grade III Glioma
09/24
08/25
NCT05627323: CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma

Active, not recruiting
1
42
US
CHM-1101 CAR-T cells, Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT/ICV dual delivery), Chlorotoxin-CD28-CD3z-CD19t-expressing CAR T-cells
Chimeric Therapeutics
Glioblastoma Multiforme of Brain
10/25
01/41

Download Options